Best results achieved so far in kidney cancer treatment: lenva and pembro

Kidney cancer has become a cancer type in which new oncological treatments have made a particularly strong impact and firsts have occurred in recent years. After 2000, 9 different targeted cancer drugs and 3 different immunotherapies for kidney cancer received FDA approval. With these advances, the median progression-free (without progression) survival time had increased from 8 months to 17 months. With the results presented at the 2021 Genitourinary Cancers Symposium and simultaneously in NEJM journal, the phase-III CLEAR study impressively extended this duration to 24 months.
According to the results of the CLEAR study, the targeted drug and immunotherapy (lenvatinib plus pembrolizumab) combination was superior to the standard treatment, sunitinib, in terms of overall survival, progression-free survival and objective response rate.
The CLEAR study also included an experimental arm investigating the lenvatinib plus everolimus combination; this arm also outperformed sunitinib for progression-free survival and objective response rate, but did not demonstrate a significant survival benefit. Lenvatinib plus everolimus had received FDA approval for advanced kidney cancer in 2016.
The study presenter, Dr. Robert J. Motzer said: "Lenvatinib plus pembrolizumab significantly improved progression-free survival, overall survival and objective response rate compared with sunitinib for the treatment of patients with advanced clear-cell renal cell carcinoma (kidney cancer). These results support lenvatinib plus pembrolizumab for the treatment of patients with advanced renal cell carcinoma as first-line treatment".
Details of the CLEAR study
The multicenter, open-label, randomized, controlled, phase III CLEAR study is a three-arm study designed to compare lenvatinib plus pembrolizumab with sunitinib, and lenvatinib plus everolimus with sunitinib, as first-line treatment for patients with advanced kidney cancer.
CLEAR is a global study, with approximately 56% of patients treated in Western Europe and North America and approximately 44% treated in other countries. Baseline characteristics were well balanced across the three treatment arms. Approximately three-quarters of the study group had previously undergone nephrectomy (surgery to remove the kidney).
The study randomly assigned 1,069 patients with advanced disease who had not previously received systemic cancer treatment to 3 arms in a 1:1:1 ratio to receive lenvatinib plus pembrolizumab, lenvatinib plus everolimus or sunitinib. The primary endpoint of the study was progression-free survival; key secondary endpoints were overall survival and objective response rate.
Results
The median progression-free (without progression) survival time assessed by independent review was 23.9 months for the lenvatinib plus pembrolizumab arm versus 9.2 months for sunitinib; a 61% improvement in favor of the combination arm ( P <.001).
Lenvatinib plus everolimus also met the primary endpoint, with a median progression-free survival of 14.7 months representing a 35% improvement in favor of this combination ( P <.001).
The progression-free survival benefit of lenvatinib plus pembrolizumab was evident in all subgroups, including all International Metastatic RCC Database Consortium (IMDC) risk groups: favorable, intermediate and low risk.
Lenvatinib plus everolimus also provided benefit versus sunitinib in subgroup analysis, but confidence intervals were wider for this combination, particularly for the poor-risk group.
Below is an indirect comparison of the treatments that have so far received FDA (United States Food and Drug Administration) approval for advanced kidney cancer treatment and the lenvatinib plus pembrolizumab combination tested in the CLEAR study discussed in this article:

An interim overall survival analysis also favored the lenvatinib plus pembrolizumab combination, with a 34% improvement compared with sunitinib ( P = .005). In contrast, there was no difference in overall survival with the lenvatinib plus everolimus and sunitinib combination.
With lenvatinib combinations, response rates were also significantly better. The confirmed objective response rate was 71% with lenvatinib plus pembrolizumab, 53.5% with lenvatinib plus everolimus and 36.1% with sunitinib.
Below is an indirect comparison of the objective response rates of approved treatments for advanced kidney cancer and lenvatinib plus pembrolizumab:

Another striking result was the high complete response rate. It was 16.1% with lenvatinib plus pembrolizumab compared with 4.2% with sunitinib. These data represent the best results reported in the treatment of advanced kidney cancer.
The median duration of response was 25.8 months with lenvatinib plus pembrolizumab, 16.6 months with lenvatinib plus everolimus and 14.6 months with sunitinib.
Below is an indirect comparison of the complete response rates of approved treatments for advanced kidney cancer and lenvatinib plus pembrolizumab:

Treatment-related grade 3 or higher adverse events occurred in 71.6% of patients in the lenvatinib plus pembrolizumab group, 73.0% in the lenvatinib plus everolimus group and 58.8% in the sunitinib group. Dose reductions and discontinuations due to treatment-related adverse events were more common with lenvatinib combinations than with sunitinib, but adverse events were comparable to those seen in other studies and no new safety signals emerged.
*
Below is a summary of the current state and recent developments in kidney cancer treatments
Sources
Was this article helpful?
Your feedback helps us improve our content.





Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.